Nidanilimab

Tax included
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
MedChemExpress 
HY-P99379

Data sheet

Size
Multiple sizes
Reactivity
Interleukin Related
Application
Cancer-programmed cell death
CAS
2171061-85-9